Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 889-898

  Giusiano, Sophie ^a,b   Secq, Veronique ^a,b   Carcopino, Xavier ^c   Carpentier, Severine ^a   Andrac, Lucile ^a   Lavaut, Marie Noelle ^a   Allasia, Claude ^a   Bonnier, Pascal ^c   Iovanna, Juan Lucio ^b   Garcia, Stephane ^a,b   Boubli, Leon ^c   Birnbaum, Daniel ^d   Charpin, Colette ^a,b  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

Multivariable fractional polynomials logistic regression; Node negative breast carcinoma; Quantitative immunohistochemical profiling; Tissue micro arrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAP KINASE ACTIVATED PROTEIN KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MOESIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P4EBP 1; PROTEIN SHARP 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DENSITOMETRY; DIGITAL IMAGING; DISEASE MARKER; EARLY CANCER; FEMALE; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; MICROSCOPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PATIENT SELECTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77749342798     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000567     Document Type: Article

References (55)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ and Panel Members: Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16: 1569-1583, 2005.
3. NCCN Clinical Practice Guidelines in Oncology: www.nccn.org, 2007.
4. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Ree CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
5. Van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH and Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
6. Van't Veer LJ, Dai H, Van't de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D: Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Nat Acad Sci USA 100: 8418-8423, 2003.
8. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D and Viens P: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64: 8558-8565, 2004.
9. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR and West M: Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101: 8431-8436, 2004.
10. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO and van de Vijver MJ: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743, 2005.
11. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
12. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F and Piccart MJ: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192, 2006.
13. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D and Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
14. Dunkler D, Michiels S and Schemper M: Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43: 745-751, 2007.
15. Michiels S, Koscielny S and Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492, 2005.
16. Simon R, Radmacher MD, Dobbin K and McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18, 2003.
17. Camp RL, Chung GG and Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327, 2002.
18. Emerson JW, Dolled-Filhart M, Harris L, Rimm DL and Tuck DP: Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform 7: 29-40, 2009.
19. Chung GG, Zerkowski MP, Ghosh S, Camp RL and Rimm DL: Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 87: 662-669, 2007.
20. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL and Rimm DL: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumour heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25: 5418-5425, 2007.
21. Pozner-Moulis S, Cregger M, Camp RL and Rimm DL: Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87: 251-260, 2007.
22. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C and Bonnier P: Tumour neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 10: 5815-5819, 2004.
23. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN and Allasia C: bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol 16: 2025-2031, 1998.
24. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN and Allasia C: Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 28: 289-296, 1997.
25. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN and Allasia C: CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Am J Clin Pathol 107: 534-541, 1997.
26. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N and Piana L: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86: 1539-1545, 1994.
27. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P and Charpin C: Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31: 49-58, 2007.
28. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L, Lavaut MN, Allasia C, Carpentier-Meunier S, Bonnier P and Charpin-Taranger C: c-Met overexpression in inflammatory breast carcinomas:automated quantification on tissue microarrays. Br J Cancer 96: 329-335, 2007.
29. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C and Gilks CM: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10: 6143-6151, 2004.
30. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
31. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, Houlgatte R, Birnbaum D and Jacquemier J: Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumour markers. Am J Pathol 161: 1223-1233, 2002.
32. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D and Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65: 767-779, 2005.
33. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D and Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284, 2006.
34. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271, 2006.
35. Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Charpin C, Xerri L, Viens P, Birnbaum D and Jacquemier J: Moesin expression is a marker of basal breast carcinomas. Int J Cancer 121: 1779-1785, 2007.
36. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Bergh J and Isola J: Basoluminal carcinoma:a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12: 4185-4191, 2006.
37. Da Silva L, Clarke C and Lakhani SR: Demystifying basal-like breast carcinomas. J Clin Pathol 60: 1328-1332, 2007.
38. Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology 52: 108-118, 2008.
39. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH and Ellis IO: Breast carcinoma with basal differentiation: A proposal for pathology definition based on basal cytokeratin expression. Histopathology 50: 434-438, 2007.
40. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P and Charpin C: Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38: 830-841, 2007.
41. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D and Sobol H: Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207: 260-268, 2005.
42. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P and Garcia S: A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 124: 2124-2134, 2009.
43. Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P and Garcia S: Quantitative immunocytochemical profiling predictive of early outcome of disease in triple-negative breast carcinomas. Int J Oncol 34: 983-993, 2009.
44. Royston P, Douglas G and Sauerbrei A: Dichotomising continuous predictors in multiple regression: a bad idea. Stat Med 25: 127-141, 2006.
45. Altman DG, Lausen B, Sauerbrei W and Schumacher M: Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835, 1994.
46. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC and Vandenbroucke JP: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370: 1453-1457, 2007.
47. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC and Vandenbroucke JP: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidem 61: 344-349, 2008.
48. Darb-Esfahani S, Faggad A, Noske, Weichert W, Buckendahl AC, Muller B, Budczies J, Roske A, Dietel M and Denker C: Phospho-mTOR and phospho-4EBP1 in endometrial adeno-carcinoma :association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135: 933-941, 2009.
49. Rao RD, Buckner JC and Sarkaria JN: Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4: 621-635, 2004.
50. Boulay A, Rudloff J, Ye Y and Zumstein-Mecker S: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11: 5319-5328, 2005.
51. Pouyssegur J, Dayan F and Mazure NM: Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 441: 437-443, 2006.
52. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P and Charpin C: Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116: 734-739, 2005.
53. Gort EH, Groot AJ, Derks van de Ven TLP, van der Groep P, Verlaan I, van Laar T, van Diest PJ, vand der Wall E and Shvartz A: Hypoxia-inducible factor-1a expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 1-5, 2006
54. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S and Jirstrom K: Hypoxia-inducible factor-2a correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68: 9212-9220, 2008.
55. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Taranger-Charpin C: Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 90: 1216-1221, 2004.